Drugs / Brigimadlin
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT05613036 | Jan 2023 → Apr 2024 | cancer | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05376800 | Nov 2022 → Jul 2025 | glioblastoma | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05372367 | Aug 2022 → Jul 2024 | cancer | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03964233 | Jun 2019 → Sep 2024 | neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03449381 | Jun 2018 → Nov 2025 | neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06619509 | Dec 2024 → Dec 2030 expected | cancer | Boehringer Ingelheim | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06084689 | Jun → Jul 2024 | biliary tract cancer, colorectal cancer, non-small cell lung carcinoma, soft tissue sarcoma +1 | Institut Bergonié | Withdrawn | No outcome recorded |
| Phase 2 | NCT05512377 | Dec 2022 → Sep 2025 | biliary tract cancer, lung neoplasm, pancreatic neoplasm, urinary bladder cancer | Boehringer Ingelheim | Terminated | No outcome recorded Stop: Business |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT05218499 | Mar 2022 → Apr 2024 | dedifferentiated liposarcoma | Boehringer Ingelheim | Completed | Missed primary |
| Phase 32 trials | ||||||
| Phase 3 | NCT06370871 | Jun 2024 → Jul 2026 | myxofibrosarcoma, undifferentiated pleomorphic sarcoma | Boehringer Ingelheim | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT06058793 | Dec 2023 → Dec 2025 | dedifferentiated liposarcoma | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Brigimadlin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06370871 ↗ |
| Known as | BI 907828 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05613036 ↗ |
| Known as | Brigimadlina | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314455 ↗ |
| Known as | Brigimadline | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314455 ↗ |
| Known as | Brigmadlin | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314455 ↗ |
| Action | Inhibit | “BI 907828 is a highly potent, oral MDM2-p53 antagonist that inhibits the interaction between p53 and MDM2, thereby restoring p53 activity.” PMID 36987836 ↗ Mar 2023 |
| Modality | Small molecule | — CHEMBL5314455 ↗ |
| Route | Oral | “Brigimadlin (BI 907828) is an oral MDM2-p53 antagonist that has shown encouraging antitumor activity in vivo.” PMID 37269344 ↗ Aug 2023 |
| Target | MDM2 | “The drug BI 907828 works differently to chemotherapy by specifically targeting a gene called MDM2.” PMID 36987836 ↗ Mar 2023 |